Search
6 results for “Vanda Pharmaceuticals Inc.”
| Case | Title | Lower Court | Docketed | Status | Tags | Question Presented |
|---|---|---|---|---|---|---|
| 24-270 | Vanda Pharmaceuticals Inc. v. Centers for Medicare & Medicaid Services, et al. | Fourth Circuit | 2024-09-10 | Denied | administrative-law agency-interpretation line-extension medicaid-rebate new-drug-application statutory-construction | Does a decision upholding an agency's statutory interpretation merely because it is 'perfectly sensible' comport with Loper Bright Enterprises v. Raim… |
| 23A1105 | Vanda Pharmaceuticals Inc. v. Centers for Medicare & Medicaid Services, et al. | Fourth Circuit | 2024-06-11 | Presumed Complete | administrative-law cms-regulation drug-pricing line-extension medicaid-drug-rebate statutory-interpretation | Whether the Centers for Medicare and Medicaid Services exceeded its statutory authority by expanding the definition of 'line extension' drug beyond Co… |
| 23-768 | Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., et al. | Federal Circuit | 2024-01-17 | Denied | federal-circuit innovation-standard ksr-international-co-v-teleflex KSR-precedent obviousness obviousness-standard patent patent-law predictable-results reasonable-expectation-of-success | Whether obviousness requires a showing of 'predictable' results, as this Court held in KSR, or a mere 'reasonable expectation of success,' as the Fede… |
| 23A403 | Electric Power Supply Association, et al. v. Federal Energy Regulatory Commission | District of Columbia | 2023-11-03 | Presumed Complete | capacity-market federal-power-act ferc market-design public-utility rate-setting | Whether capacity market offers constitute 'rates' under Section 205 of the Federal Power Act, such that public utilities retain the primary right to s… |
| 23A344 | Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., et al. | Federal Circuit | 2023-10-17 | Presumed Complete | KSR-standard obviousness patent-law pharmaceutical-patents predictable-result prior-art | Whether the Federal Circuit's obviousness analysis complies with the Supreme Court's standard in KSR International Co. v. Teleflex Inc. by requiring t… |
| 18-817 | Hikma Pharmaceuticals USA Inc., et al. v. Vanda Pharmaceuticals Inc. | Federal Circuit | 2018-12-27 | Denied | generic-drugs inventive-concept medical-patent medical-treatment method-of-treatment natural-law patent-eligibility routine-and-conventional section-101 | Whether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural … |